The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion-Reference-Cited by-同舟云学术

The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion

Published:2011-03 Issue:3 Volume:147 Page:428-432
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Ibanez Borja,Cimmino Giovanni,Prat-González Susanna,Vilahur Gemma,Hutter Randolph,García Mario J.,Fuster Valentin,Sanz Javier,Badimon Lina,Badimon Juan J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance;Ibanez;Circulation,2007

2. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction

3. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction;Halkin;J Am Coll Cardiol,2004

4. Role of intravenous beta-blockers in the treatment of ST-elevation myocardial infarction: of mice (dogs, pigs) and men;Bates;Circulation,2007

5. Modulation of neutrophil migration and superoxide anion release by metoprolol;Dunzendorfer;J Mol Cell Cardiol,2000

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1 and AKT Overexpressing Adipose-Derived Mesenchymal Stem Cells Enhance Myocardial Protection by Upregulating CD25+ T Cells in Acute Myocardial Infarction Rat Model;International Journal of Molecular Sciences;2023-12-21

2. No robust reduction of infarct size and no-reflow by metoprolol pretreatment in adult Göttingen minipigs;Basic Research in Cardiology;2023-06-08

3. Cardioprotective Effects of a Selective c-Jun N-terminal Kinase Inhibitor in a Rat Model of Myocardial Infarction;Biomedicines;2023-02-27

4. Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning;Pharmacological Reviews;2022-12-08

5. Neutrophils in aging and aging‐related pathologies;Immunological Reviews;2022-10-31